US appeals court supports Amgen in NFkappaB dispute with Ariad
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit has upheld a lower court's summary judgment opinion, which concluded that Amgen and Wyeth's arthritis treatment Enbrel (etanercept), a TNF-blocker, does not infringe Ariad's US NFkappaB patent.